TAH 6601
Alternative Names: TAH-6601Latest Information Update: 28 Sep 2024
Price :
$50 *
At a glance
- Originator TAHO Pharmaceuticals
- Class Antiepileptic drugs
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Lennox-Gastaut syndrome
Most Recent Events
- 28 Sep 2024 No recent reports of development identified for preclinical development in Lennox-Gastaut-syndrome in China (Transdermal, Patch)
- 19 Sep 2022 Preclinical studies are still underway for Lennox-Gastaut syndrome in China (TAHO Pharmaceuticals pipeline, September 2022)
- 28 Dec 2021 No recent reports of development identified for preclinical development in Lennox-Gastaut-syndrome in China (Transdermal, Patch)